XASEVTAK
Market cap3mUSD
Dec 24, Last price
0.38USD
1D
9.51%
1Q
-18.79%
IPO
-100.00%
Name
Ra Medical Systems Inc
Chart & Performance
P/E
—
P/S
6.88
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
275.26%
Rev. gr., 5y
-41.14%
Revenues
442k
+3,057.14%
Net income
-71m
L+162.69%
CFO
-21m
L-8.64%
Earnings
May 05, 2025
Profile
Ra Medical Systems, Inc., a medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular immune-mediated inflammatory diseases. It offers destruction of arteriosclerotic blockages by laser radiation ablation, a minimally invasive excimer laser and single-use catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. The company sells its products primarily through distributors in the United States. Ra Medical Systems, Inc. was incorporated in 2002 and is headquartered in Carlsbad, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 442 3,057.14% | 14 -36.36% | 22 -99.50% | |||||
Cost of revenue | 505 | 10,038 | 13,813 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (63) | (10,024) | (13,791) | |||||
NOPBT Margin | ||||||||
Operating Taxes | 3 | 4 | ||||||
Tax Rate | ||||||||
NOPAT | (63) | (10,027) | (13,795) | |||||
Net income | (70,572) 162.69% | (26,865) 7.16% | (25,070) -30.45% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 8,238 | 18,906 | 15,528 | |||||
BB yield | -37.08% | -31.04% | -19.71% | |||||
| Debt | ||||||||
Debt current | 275 | 37 | 283 | |||||
Long-term debt | 285 | 212 | 4,245 | |||||
Deferred revenue | ||||||||
Other long-term liabilities | 6,974 | 159 | ||||||
Net debt | (3,005) | (15,611) | (10,517) | |||||
| Cash flow | ||||||||
Cash from operating activities | (20,619) | (22,568) | (27,625) | |||||
CAPEX | (76) | (17) | (265) | |||||
Cash from investing activities | (61) | 21 | 3,802 | |||||
Cash from financing activities | 8,386 | 23,361 | 14,962 | |||||
FCF | (167) | (6,253) | (12,019) | |||||
| Balance | ||||||||
Cash | 3,565 | 15,859 | 15,045 | |||||
Long term investments | ||||||||
Excess cash | 3,543 | 15,858 | 15,044 | |||||
Stockholders' equity | (275,709) | (205,127) | (178,264) | |||||
Invested Capital | 304,248 | 214,424 | 194,201 | |||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 5,495 | 1,034 | 101 | |||||
Price | 4.04 -93.14% | 58.90 -92.45% | 780.00 -79.00% | |||||
Market cap | 22,216 -63.52% | 60,903 -22.69% | 78,780 -37.59% | |||||
EV | 19,211 | 45,292 | 68,263 | |||||
EBITDA | 2,012 | (9,603) | (12,226) | |||||
EV/EBITDA | 9.55 | |||||||
Interest | 3,078 | |||||||
Interest/NOPBT | ||||||||